Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Thursday after the bell. Here’s what investors should know. BioMarin Pha...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
BioMarin Pharmaceutical trades at $59.99 per share and has stayed right on track with the overall market, gaining 6.5% over the last six months. At the same ...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today does...
What Happened? Shares of biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) jumped 7.3% in the afternoon session after the company announced positive resu...
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...
BioMarin’s first quarter saw revenue growth driven by continued demand for its enzyme therapies and Voxzogo, but the company missed Wall Street’s revenue and...
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.8% year on year to $766.2 millio...
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.8% year on year to $766.2 millio...
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting results this Monday afternoon. Here’s what to look for. BioMarin Pharmaceutical beat ...
